COPD: Emphysema and Chronic Bronchitis

Core Idea

COPD comprises emphysema (alveolar destruction and loss of elastic recoil) and chronic bronchitis (mucus hypersecretion and small-airway inflammation). Tobacco smoke triggers abnormal inflammation, protease-antiprotease imbalance, and oxidative stress.

How It's Best Learned

Distinguish pathology: emphysema → air trapping and dyspnea; bronchitis → productive cough and bronchial edema. Understand FEV1 decline as a marker of disease progression and the role of alpha-1 antitrypsin deficiency.

Common Misconceptions

COPD is not purely obstructive—emphysematous lungs have loss of elastic recoil. Smoking cessation halts decline but does not reverse destruction. Hyperinflation is a primary mechanism of dyspnea, not a secondary consequence.

Explainer

Recall from your respiratory anatomy that the lungs are elastic organs — when you inhale, you actively stretch them with your diaphragm and chest wall, and normal exhalation is passive, driven by elastic recoil snapping the lung back to its resting volume. This recoil is generated by the collagen-elastin scaffolding of the alveolar walls. Now imagine that scaffold being slowly destroyed. That is emphysema: tobacco smoke activates alveolar macrophages and neutrophils that release proteases (particularly neutrophil elastase) to destroy the very tissue that should recoil. The body has a natural counterbalance — alpha-1 antitrypsin (AAT) — which normally neutralizes these proteases. When smoke overwhelms AAT, or when someone inherits a deficiency, the protease-antiprotease balance tips toward destruction.

The structural consequence is progressive alveolar wall breakdown and air trapping. Without elastic recoil to drive passive exhalation, air accumulates behind collapsed small airways. The chest hyperinflates — lungs take up more space at rest — which flattens the diaphragm and puts the respiratory muscles at a mechanical disadvantage. This is why emphysema patients breathe at high lung volumes using accessory muscles: they're trying to restore the stretch that would normally trigger recoil. Dyspnea in emphysema is largely a mechanics problem, not a gas exchange problem — at least early on. The classic "pink puffer" breathes rapidly with pursed lips, which creates auto-PEEP (back-pressure that splints open small airways), a behavioral adaptation to the recoil deficit.

Chronic bronchitis is a separate but frequently co-occurring pathology, defined clinically as a productive cough for at least three months in two consecutive years. Smoke triggers chronic airway inflammation — mucus glands hypertrophy (Reid index increases), goblet cell metaplasia adds more mucus-secreting cells, and edema thickens the bronchial wall. The result is a narrowed airway lumen filled with secretions. Unlike emphysema, the problem here is intrinsic airway obstruction rather than loss of recoil. The classic "blue bloater" retains CO₂ because the drive to breathe becomes blunted over years of hypercapnia — the respiratory centers adapt to elevated CO₂ and rely more on hypoxic drive.

From the chronic inflammation prerequisite, you know that sustained inflammatory stimuli cause tissue remodeling — fibrosis, smooth muscle hypertrophy, structural reorganization. In the airways, this means airway remodeling that further narrows the lumen even after inflammation is suppressed. This is why smoking cessation halts the accelerated FEV₁ decline but does not restore lost lung function: the structural changes are irreversible. Spirometry captures this as a fixed reduction in the FEV₁/FVC ratio — distinguishing obstructive disease (COPD, asthma) from restrictive disease — and the degree of FEV₁ impairment stages severity and predicts prognosis.